In Thickins of it
TPG Capital’s man in Asia expected to plead guilty this morning.
Good morning.
TPG Capital has a key-man problem in Asia at the worst possible moment, and it walks into Waverley Local Court this morning.
Co-head of Asia Joel Thickins, who effectively runs the investment committee while his co-head works the Middle East fundraising trail, is expected to plead guilty (per the AFR) and ask for leniency over the five-car crash and two refused breath tests that put him on paid leave earlier this month.
Best case for Thickins is a guilty finding with no conviction recorded (The Australian says he’s lawyered up with Streeton’s Justin Wong, a self-styled white-collar and DUI specialist).
But with Thickins sidelined and a US law firm crawling over the incident, TPG has reportedly spent a fortnight reassuring rattled LPs and shelved plans for a new regional fund, just as Bain, EQT and Blackstone hoover up tens of billions across Asia. Raising a fund is hard enough without your dealmaker-in-chief in the dock.
| ▲ | ASX 200 | 8,823 | +0.64% |
| ▲ | ASX futures | 8,827 | +0.06% |
| ▲ | S&P 500 | 7,440 | +1.17% |
| ▲ | NASDAQ | 25,820 | +2.07% |
| ▼ | AUD/USD | 0.69 | -0.09% |
| ▲ | Bitcoin | 60,430 | +1.70% |
ASX 200 as at market close. Bitcoin in USD.
Market movers
| ▲ | ASX:NEU | $16.60 | +36.07% |
Shares in Neuren Pharmaceuticals surged on Monday after European regulators took the biotech’s Rett syndrome drug Daybue a decisive step closer to market. The European Medicines Agency’s human medicines committee recommended the treatment for marketing authorisation, clearing the path towards approval across the bloc.